Literature DB >> 8418271

Myocardial uptake of metaiodobenzylguanidine in patients with left ventricular hypertrophy secondary to valvular aortic stenosis.

D Fagret1, J E Wolf, G Vanzetto, E Borrel.   

Abstract

UNLABELLED: The time course of myocardial uptake of metaiodobenzylguanidine ([123I]MIBG) was studied in 26 patients: seven control subjects (Group 1) and 13 patients with left ventricular hypertrophy secondary to valvular aortic stenosis. Seven of these had received no treatment (Group 2) and six were receiving amiodarone or digoxin (Group 3); six heart transplant recipients were investigated for extra neuronal myocardial uptake of [123I]MIBG (Group 4). The index of myocardial [123I]MIBG uptake was lower in Groups 2 and 3 than in Group 1 (Group 2: 1.42 +/- 0.07, p < 0.001; Group 3: amiodarone, 1.30 +/- 0.10, p < 0.05; digoxin, 1.22 +/- 0.06, p < 0.01; Group I: 1.83 +/- 0.18) and lower in Group 3 than in Group 2. Patients of Group 4 showed a much lower mean index of myocardial [123I]MIBG uptake than the control group (1.07 +/- 0.08, p < 0.001). IN
CONCLUSION: 1. Patients with left ventricular hypertrophy secondary to valvular aortic stenosis were found to have lower myocardial [123I]MIBG activity and rapid washout than the control subjects. 2. Amiodarone and digoxin partially inhibited myocardial [123I] MIBG uptake. 3. Extra neuronal myocardial uptake of [123I]MIBG in humans only accounts for 13% of the total cardiac activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418271

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  15 in total

Review 1.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

2.  Effects of therapy with amiodarone on clinical, functional, and cardiac sympathetic innervation in patients with idiopathic dilated cardiomyopathy.

Authors:  Albert Flotats; Ignasi Carrió
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

3.  Interaction of metaiodobenzylguanidine with cardioactive drugs: an in vitro study.

Authors:  F Huguet; D Fagret; M Caillet; A Piriou; J C Besnard; D Guilloteau
Journal:  Eur J Nucl Med       Date:  1996-05

Review 4.  Management decisions in valvular heart disease: the role of radionuclide-based assessment of ventricular function and performance.

Authors:  J S Borer; D Wencker; C Hochreiter
Journal:  J Nucl Cardiol       Date:  1996 Jan-Feb       Impact factor: 5.952

Review 5.  Imaging of myocardial sympathetic innervation with metaiodobenzylguanidine.

Authors:  M W Dae
Journal:  J Nucl Cardiol       Date:  1994 Mar-Apr       Impact factor: 5.952

Review 6.  Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature.

Authors:  Arnold F Jacobson; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2015-05-15       Impact factor: 5.952

7.  123I-MIBG myocardial imaging in hypertensive patients: abnormality progresses with left ventricular hypertrophy.

Authors:  I Mitani; S Sumita; N Takahashi; H Ochiai; M Ishii
Journal:  Ann Nucl Med       Date:  1996-08       Impact factor: 2.668

Review 8.  Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry.

Authors:  A R Wafelman; C A Hoefnagel; R A Maes; J H Beijnen
Journal:  Eur J Nucl Med       Date:  1994-06

9.  (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

Authors:  S Orimo; E Ozawa; S Nakade; T Sugimoto; H Mizusawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-08       Impact factor: 10.154

10.  Measurement of myocardial accumulation of 123I-metaiodobenzylguanidine for studying cardiac autonomic neuropathy in diabetes mellitus.

Authors:  M Mäntysaari; J Kuikka; J Mustonen; K Tahvanainen; E Vanninen; E Länsimies; M Uusitupa
Journal:  Clin Auton Res       Date:  1996-06       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.